Emergent BioSolutions Statistics
Total Valuation
EBS has a market cap or net worth of $340.20 million. The enterprise value is $788.70 million.
| Market Cap | 340.20M |
| Enterprise Value | 788.70M |
Important Dates
The next estimated earnings date is Wednesday, October 28, 2026, after market close.
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EBS has 51.27 million shares outstanding. The number of shares has decreased by -5.35% in one year.
| Current Share Class | 51.27M |
| Shares Outstanding | 51.27M |
| Shares Change (YoY) | -5.35% |
| Shares Change (QoQ) | -8.67% |
| Owned by Insiders (%) | 4.30% |
| Owned by Institutions (%) | 88.99% |
| Float | 49.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.44 |
| Forward PS | 0.53 |
| PB Ratio | 1.00 |
| P/TBV Ratio | 4.30 |
| P/FCF Ratio | 3.98 |
| P/OCF Ratio | 3.50 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.40, with an EV/FCF ratio of 9.20.
| EV / Earnings | n/a |
| EV / Sales | 1.03 |
| EV / EBITDA | 3.40 |
| EV / EBIT | 5.63 |
| EV / FCF | 9.20 |
Financial Position
The company has a current ratio of 5.42, with a Debt / Equity ratio of 1.72.
| Current Ratio | 5.42 |
| Quick Ratio | 2.68 |
| Debt / Equity | 1.72 |
| Debt / EBITDA | 2.53 |
| Debt / FCF | 6.85 |
| Interest Coverage | 2.76 |
Financial Efficiency
Return on equity (ROE) is -40.29% and return on invested capital (ROIC) is 16.18%.
| Return on Equity (ROE) | -40.29% |
| Return on Assets (ROA) | 6.93% |
| Return on Invested Capital (ROIC) | 16.18% |
| Return on Capital Employed (ROCE) | 14.13% |
| Weighted Average Cost of Capital (WACC) | 10.61% |
| Revenue Per Employee | $855,778 |
| Profits Per Employee | -$196,444 |
| Employee Count | 900 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, EBS has paid $30.80 million in taxes.
| Income Tax | 30.80M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.46% in the last 52 weeks. The beta is 2.34, so EBS's price volatility has been higher than the market average.
| Beta (5Y) | 2.34 |
| 52-Week Price Change | -18.46% |
| 50-Day Moving Average | 6.27 |
| 200-Day Moving Average | 8.78 |
| Relative Strength Index (RSI) | 57.01 |
| Average Volume (20 Days) | 1,237,596 |
Short Selling Information
The latest short interest is 10.84 million, so 21.15% of the outstanding shares have been sold short.
| Short Interest | 10.84M |
| Short Previous Month | 10.03M |
| Short % of Shares Out | 21.15% |
| Short % of Float | 22.10% |
| Short Ratio (days to cover) | 7.24 |
Income Statement
In the last 12 months, EBS had revenue of $770.20 million and -$176.80 million in losses. Loss per share was -$3.39.
| Revenue | 770.20M |
| Gross Profit | 388.50M |
| Operating Income | 140.50M |
| Pretax Income | -146.00M |
| Net Income | -176.80M |
| EBITDA | 232.40M |
| EBIT | 140.50M |
| Loss Per Share | -$3.39 |
Balance Sheet
The company has $139.70 million in cash and $588.20 million in debt, with a net cash position of -$448.50 million or -$8.75 per share.
| Cash & Cash Equivalents | 139.70M |
| Total Debt | 588.20M |
| Net Cash | -448.50M |
| Net Cash Per Share | -$8.75 |
| Equity (Book Value) | 341.40M |
| Book Value Per Share | 6.65 |
| Working Capital | 543.20M |
Cash Flow
In the last 12 months, operating cash flow was $97.70 million and capital expenditures -$11.80 million, giving a free cash flow of $85.90 million.
| Operating Cash Flow | 97.70M |
| Capital Expenditures | -11.80M |
| Depreciation & Amortization | 91.90M |
| Net Borrowing | -117.00M |
| Free Cash Flow | 85.90M |
| FCF Per Share | $1.68 |
Margins
Gross margin is 50.44%, with operating and profit margins of 18.24% and -22.96%.
| Gross Margin | 50.44% |
| Operating Margin | 18.24% |
| Pretax Margin | -18.96% |
| Profit Margin | -22.96% |
| EBITDA Margin | 30.17% |
| EBIT Margin | 18.24% |
| FCF Margin | 11.15% |
Dividends & Yields
EBS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 5.35% |
| Shareholder Yield | 5.35% |
| Earnings Yield | -51.70% |
| FCF Yield | 25.12% |
Analyst Forecast
The average price target for EBS is $11.00, which is 65.79% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.00 |
| Price Target Difference | 65.79% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | -5.44% |
| EPS Growth Forecast (3Y) | 0.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EBS has an Altman Z-Score of 1.65 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 6 |